期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 66, 期 3, 页码 1761-1777出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01574
关键词
-
Novel bicyclic NNRTIs with improved solubility and high antiviral activity against HIV-1 were designed and prepared. The binding modes of these compounds to reverse transcriptase were also studied by X-ray crystallography.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent cornerstones of current regimens for treatment of human immunodeficiency virus type 1 (HIV-1) infections. However, NNRTIs usually suffer from low aqueous solubility and the emergence of resistant viral strains. In the present work, novel bicyclic NNRTIs derived from etravirine (ETV) and rilpivirine (RPV), bearing modified purine, tetrahydropteridine, and pyrimidodiazepine cores, were designed and prepared. Compounds 2, 4, and 6 carrying the acrylonitrile moiety displayed single-digit nanomolar activities against the wild-type (WT) virus (EC50 = 2.5, 2.7, and 3.0 nM, respectively), where the low nanomolar activity was retained against HXB2 (EC50 = 2.2-2.8 nM) and the K103N and Y181C mutated strains (fold change, 1.2- 6.7x). Most importantly, compound 2 exhibited significantly improved phosphate-buffered saline solubility (10.4 mu M) compared to ETV and RPV (MUCH LESS-THAN1 mu M). Additionally, the binding modes of compounds 2, 4, and 6 to the reverse transcriptase were studied by X-ray crystallography.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据